Pulse Biosciences (PLSE) just cleared a key regulatory hurdle, with the FDA signing off on its Investigational Device Exemption for the nPulse Cardiac Catheter Ablation System in atrial fibrillation, ...
As of Friday, December 12, Pulse Biosciences, Inc.’s PLSE share price has surged by 6.69%, which has investors questioning if ...
Pulse Biosciences announced today that the FDA granted investigational device exemption (IDE) for a pulsed field ablation (PFA) study.
Pulse Biosciences today announced a collaboration aimed at using its pulsed field ablation (PFA) technology for thyroid ...
Shorter, nanosecond pulses for treating atrial fibrillation differentiate the company’s approach from existing pulsed field ...
This single-arm, multicenter, prospective study is designed to demonstrate primary safety and effectiveness of the nsPFA Cardiac Catheter System for the treatment of recurrent drug-resistant ...
Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission “Since joining the Company’s Board last year I have ...
An announcement from Pulse Biosciences ( ($PLSE) ) is now available. On December 18, 2025, Pulse Biosciences announced that the U.S. Food and Drug ...
The Company’s nsPFA™ System demonstrates the ability to provide cardiac ablation and mapping capabilities with a single catheter in preclinical studies The Company collaborated with CardioNXT to ...
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) ...